• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $IMA

    ImageneBio Inc.

    Subscribe to $IMA
    $IMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    IPO Year: 2021

    Exchange: NASDAQ

    Recent Analyst Ratings for ImageneBio Inc.

    DatePrice TargetRatingAnalyst
    10/24/2025$30.00Outperform
    Leerink Partners
    See more ratings

    ImageneBio Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Leerink Partners initiated coverage on ImageneBio with a new price target

    Leerink Partners initiated coverage of ImageneBio with a rating of Outperform and set a new price target of $30.00

    10/24/25 9:00:36 AM ET
    $IMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    ImageneBio Inc. Press Releases

    Fastest customizable press release news feed in the world

    View All

    ImageneBio to Participate in Fourth Quarter 2025 Investor Conferences

    SAN DIEGO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (NASDAQ:IMA, "Imagene, " "Company")), a clinical-stage biotechnology company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases, including IMG-007, an anti-OX40 monoclonal antibody with multiple differentiating features, today announced management participation in fourth quarter investor conferences. 2025 Stifel Healthcare ConferenceFireside Chat: Thursday, November 13, 9:20am ESTNew York, NY Piper Sander 37th Annual Healthcare ConferenceFireside Chat: Thursday, December 4, 10:00am ESTNew York, NY To access the live webcasts or subsequent archived recordings of the presentation and f

    11/6/25 8:30:00 AM ET
    $IMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    SAN DIEGO, Aug. 01, 2025 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (NASDAQ:IMA) ("ImageneBio"), a clinical stage biotechnology company dedicated to developing treatments for immunological/autoimmune and inflammatory ("I&I") diseases, granted equity awards to Dr. Kristin Yarema, ImageneBio's recently appointed Chief Executive Officer, on July 28, 2025 that were recommended by the Compensation Committee of its Board of Directors (the "Board") and approved by the Board. The grant included (i) inducement stock options to purchase 436,080 shares of common stock; and (ii) inducement restricted stock units ("RSUs") for 153,505 shares of common stock (together, the "Inducement Awards"). The Inducement

    8/1/25 4:15:00 PM ET
    $IMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    ImageneBio Inc. SEC Filings

    View All

    SEC Form 8-K filed by ImageneBio Inc.

    8-K - ImageneBio, Inc. (0001835579) (Filer)

    11/5/25 4:05:32 PM ET
    $IMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 424B3 filed by ImageneBio Inc.

    424B3 - ImageneBio, Inc. (0001835579) (Filer)

    11/5/25 4:07:46 PM ET
    $IMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 424B3 filed by ImageneBio Inc.

    424B3 - ImageneBio, Inc. (0001835579) (Filer)

    10/30/25 4:35:37 PM ET
    $IMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    ImageneBio Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Entry into a Material Definitive Agreement

    8-K - ImageneBio, Inc. (0001835579) (Filer)

    10/29/25 8:00:06 AM ET
    $IMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 8-K filed by ImageneBio Inc.

    8-K - ImageneBio, Inc. (0001835579) (Filer)

    10/22/25 9:03:11 AM ET
    $IMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 8-K filed by ImageneBio Inc.

    8-K - ImageneBio, Inc. (0001835579) (Filer)

    10/10/25 4:45:56 PM ET
    $IMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form EFFECT filed by ImageneBio Inc.

    EFFECT - ImageneBio, Inc. (0001835579) (Filer)

    9/16/25 12:15:17 AM ET
    $IMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form S-1 filed by ImageneBio Inc.

    S-1 - ImageneBio, Inc. (0001835579) (Filer)

    9/8/25 4:18:04 PM ET
    $IMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: ImageneBio Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits

    8-K/A - ImageneBio, Inc. (0001835579) (Filer)

    8/12/25 5:19:19 PM ET
    $IMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 8-K filed by ImageneBio Inc.

    8-K - ImageneBio, Inc. (0001835579) (Filer)

    8/5/25 5:15:17 PM ET
    $IMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    ImageneBio Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Slattery Joseph P

    3 - ImageneBio, Inc. (0001835579) (Issuer)

    11/7/25 5:15:40 PM ET
    $IMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Wang Stephen Hui was granted 250,721 shares (SEC Form 4)

    4 - ImageneBio, Inc. (0001835579) (Issuer)

    10/10/25 4:37:16 PM ET
    $IMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by new insider Wang Stephen Hui

    3 - ImageneBio, Inc. (0001835579) (Issuer)

    10/10/25 4:34:58 PM ET
    $IMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Wang Jonathan Jian was granted 1,115,005 shares (SEC Form 4)

    4 - ImageneBio, Inc. (0001835579) (Issuer)

    8/15/25 4:51:56 PM ET
    $IMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by new insider Wang Jonathan Jian

    3 - ImageneBio, Inc. (0001835579) (Issuer)

    8/15/25 4:49:59 PM ET
    $IMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Chief Medical Officer Lu Yufang

    4 - ImageneBio, Inc. (0001835579) (Issuer)

    8/7/25 5:29:10 PM ET
    $IMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by new insider Lu Yufang

    3 - ImageneBio, Inc. (0001835579) (Issuer)

    8/7/25 5:26:56 PM ET
    $IMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care